| Symbol | ALXO |
|---|---|
| Name | ALX ONCOLOGY HOLDINGS INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080 |
| Telephone | 650-466-7125 |
| Fax | — |
| — | |
| Website | https://www.alxoncology.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a dont eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Additional info from NASDAQ: |
New Form ARS - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-164310 <b>Size:</b> 6 MB
Read moreNew Form DEF 14A - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-163936 <b>Size:</b> 10 MB
Read moreKnight Jeff E. 🟢 acquired 800.0K shares (1 derivative) of ALX ONCOLOGY HOLDINGS INC (ALXO) at $1.68 ($1.3M) Transaction Date: Apr 16, 2026 | Filing ID: 161558
Read moreKlencke Barbara 🟢 acquired 100.0K shares (1 derivative) of ALX ONCOLOGY HOLDINGS INC (ALXO) at $1.68 Transaction Date: Apr 16, 2026 | Filing ID: 161557
Read moreALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Read moreNew Form 3 - ALX ONCOLOGY HOLDINGS INC <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001193125-26-161540 <b>Size:</b> 12 KB
Read more(70% Positive) ALX ONCOLOGY HOLDINGS INC (ALXO) Announces Clinical Development Update
Read moreALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
Read moreLettmann Jason 🔴 sold 12.3K shares of ALX ONCOLOGY HOLDINGS INC (ALXO) at $2.17 Transaction Date: Mar 19, 2026 | Filing ID: 119705
Read morePinto Shelly 🔴 sold 903 shares of ALX ONCOLOGY HOLDINGS INC (ALXO) at $2.17 Transaction Date: Mar 19, 2026 | Filing ID: 119703
Read more